Inhibition of bromodomain and extra‐terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia

The development of drugs able to target BTK, PI3k‐delta and BCL2 has dramatically improved chronic lymphocytic leukaemia (CLL) therapies. However, drug resistance to these therapies has already been reported due to non‐recurrent changes in oncogenic pathways and genes expression signatures. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Carrà, Giovanna, Nicoli, Paolo, Lingua, Marcello Francesco, Maffeo, Beatrice, Cartellà, Antonio, Circosta, Paola, Brancaccio, Mara, Parvis, Guido, Gaidano, Valentina, Guerrasio, Angelo, Saglio, Giuseppe, Taulli, Riccardo, Morotti, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991693/
https://www.ncbi.nlm.nih.gov/pubmed/31821686
http://dx.doi.org/10.1111/jcmm.14857

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991693/
https://www.ncbi.nlm.nih.gov/pubmed/31821686
http://dx.doi.org/10.1111/jcmm.14857

Ejemplares similares